Stock XLSCF XLIE SCIE
Add to a list
To use this feature you must be a member
Log inSign up

Financials XLIE SCIE OTC Markets

Equities

XLSCF

CH0461929603

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for XLIE SCIE -.--% -.--%
23/04 Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
29/02 Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023 2024
Capitalization 1 156.9 279 199.6
Enterprise Value (EV) 1 216.9 335.2 264.8
P/E ratio 14.9 x 24 x -53 x
Yield - - -
Capitalization / Revenue 153 x 282 x 250 x
EV / Revenue 211 x 339 x 331 x
EV / EBITDA -43.7 x -78.4 x -66.2 x
EV / FCF -46.3 x - -53 x
FCF Yield -2.16% - -1.89%
Price to Book - - -
Nbr of stocks (in thousands) 5,284 5,590 5,703
Reference price 2 29.70 49.90 35.00
Announcement Date 20/04/23 29/02/24 -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 0.3968 0.8061 1.028 0.9884 0.8
EBITDA 1 -2.964 - -4.961 -4.278 -4
EBIT 1 -3.025 - -20.98 -20.31 -4.19
Operating Margin -762.31% - -2,041.2% -2,054.54% -523.75%
Earnings before Tax (EBT) 1 21.26 - 4.039 4.534 -5
Net income 1 21.62 53.42 14.31 14.88 -4
Net margin 5,449.53% 6,627.03% 1,392.26% 1,505.33% -500%
EPS 2 - - 2.000 2.080 -0.6600
Free Cash Flow 1 -0.4577 - -4.688 - -5
FCF margin -115.35% - -456.01% - -625%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 31/03/21 29/04/22 20/04/23 29/02/24 -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt 1 50.8 - 60 56.2 65.2
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -17.15 x - -12.1 x -13.14 x -16.3 x
Free Cash Flow 1 -0.46 - -4.69 - -5
ROE (net income / shareholders' equity) 19% - - - -
ROA (Net income/ Total Assets) 12.7% - - - -
Assets 1 169.9 - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - - 0.08 - 1
Capex / Sales - - 7.8% - 125%
Announcement Date 31/03/21 29/04/22 20/04/23 29/02/24 -
1CHF in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for XLIE SCIE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
35 CHF
Average target price
68 CHF
Spread / Average Target
+94.29%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+21.74% 46.81B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.97% 41.37B
LONZA GROUP AG Stock Lonza Group AG
+47.07% 41.29B
CELLTRION, INC. Stock Celltrion, Inc.
-3.52% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.12% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.37% 19.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.18% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.04% 12.08B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.39% 11.96B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLS Stock
  4. XLSCF Stock
  5. Financials XLIE SCIE
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW